This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Adventrx: FDA Rejects Lung Cancer Drug

SAN DIEGO ( TheStreet) -- The market value of Adventrx Pharmaceuticals (ANX) will plunge Wednesday (and deservedly so) after U.S. regulators rejected the company's lung cancer drug Exelbine.

The setback raises serious and legitimate questions about Adventrx's qualifications as a drug developer and should pop the speculative trading bubble that's over-inflated the company's valuation all summer.

Adventrx shares closed Tuesday at $2.54 ahead the announcement of the Exelbine rejection. The company isn't worth more than the cash on its books -- $40 million, or about $1.11 a share. For its sheer stupidity and the fact that Adventrx still intends to spend (waste) its cash, the stock should trade below cash value.

That's because Adventrx appears to lack any ability to get even the simplest of drugs approved by the U.S. Food and Drug Administration. Exelbine is a proprietary reformulation of the chemotherapy drug vinorelbine -- nothing fancy or complicated about it. The only requirement to get Exelbine approved was to show in a very straightforward and small study that Exelbine was biologically equivalent to vinorelbine.

Yet somehow, Adventrx managed to screw up this simple task. Unbelievable.

Based on inspections of clinical trial sites, FDA reviewers were unable to verify the "authenticity" of the drugs used in the bioequivalence study, which put the results of the study in question, according to Adventrx's explanation of the FDA rejection letter.

Step back a moment and think about what that means: FDA is accusing Adventrx of running a clinical study so mismanaged that determining which lung cancer patients received either Exelbine or vinorelbine could not be determined.


If that's not enough, FDA still has unanswered questions about the quality and manufacturing of Exelbine, according to Adventrx. Yet these were concerns that Adventrx was supposed to have assuaged after FDA issued refuse-to-file letter for Exelbine in March 2010.

In July, I argued that Adventrx -- trading near $4 a share at the time -- was wildly over-valued based on the tiny commercial opportunity for Exelbine. I assumed Adventrx would manage to get Exelbine approved, even though the drug would barely generate any revenue. I was right about the stock for the wrong reasons. I gave Adventrx too much credit. I didn't believe the company could be as incompetent as it's now proven to be.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ANX $0.73 0.00%
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.81 0.50%
TSLA $222.56 -4.20%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs